Tom Chivers is a London-based science writer. He grew up in Oxford, before graduating from the University of Liverpool with a first-class degree in philosophy; he then took a Master’s degree at the King’s College London Centre of Medical Law and Ethics. He worked for the Daily Telegraph for seven years from 2007 to 2014, and was a science writer at BuzzFeed UK from 2015 to 2018. He has received several awards for his journalism, including the ‘Explaining the facts’ category in the Royal Statistical Society’s Statistical Excellence in Journalism awards, and was nominated for the British Journalism Award in science writing in 2017. His first book, The Rationalists: Artificial intelligence and the geeks who want to save the world, will be published by Weidenfeld & Nicolson in summer 2019.
Tom Chivers
From this contributor
Studying genetics in the age of big data
New biomedical techniques, like next-generation genome sequencing, are creating vast amounts of data and transforming the scientific landscape.
Studying genetics in the age of big data
Explore more from The Transmitter
Neuro’s ark: Understanding fast foraging with star-nosed moles
“MacArthur genius” Kenneth Catania outlined the physiology behind the moles’ stellar foraging skills two decades ago. Next, he wants to better characterize their food-seeking behavior.
Neuro’s ark: Understanding fast foraging with star-nosed moles
“MacArthur genius” Kenneth Catania outlined the physiology behind the moles’ stellar foraging skills two decades ago. Next, he wants to better characterize their food-seeking behavior.
Largest leucovorin-autism trial retracted
A reanalysis of the data revealed errors and failed to replicate the results.
Largest leucovorin-autism trial retracted
A reanalysis of the data revealed errors and failed to replicate the results.
NIH scraps policy that classified basic research in people as clinical trials
The policy aimed to increase the transparency of research in humans but created “a bureaucratic nightmare” for basic neuroscientists.
NIH scraps policy that classified basic research in people as clinical trials
The policy aimed to increase the transparency of research in humans but created “a bureaucratic nightmare” for basic neuroscientists.